US 12,259,380 B2
Oligonucleotides for inducing paternal UBE3A expression
Veronica Costa, Basel (CH); Maj Hedtjärn, Hørsholm (DK); Marius Hoener, Basel (CH); Ravi Jagasia, Basel (CH); Mads Aaboe Jensen, Hørsholm (DK); Christoph Patsch, Basel (CH); Lykke Pedersen, Hørsholm (DK); and Søren Vestergaard Rasmussen, Hørsholm (DK)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Feb. 22, 2023, as Appl. No. 18/172,707.
Application 18/172,707 is a continuation of application No. 17/581,089, filed on Jan. 21, 2022, granted, now 11,852,627.
Application 17/581,089 is a continuation of application No. 16/933,445, filed on Jul. 20, 2020, granted, now 11,320,421, issued on May 3, 2022.
Application 16/933,445 is a continuation of application No. 16/663,024, filed on Oct. 24, 2019, granted, now 10,718,753, issued on Jul. 21, 2020.
Application 16/663,024 is a continuation of application No. 16/388,714, filed on Apr. 18, 2019, granted, now 10,739,332, issued on Aug. 11, 2020.
Application 16/388,714 is a continuation of application No. 15/351,113, filed on Nov. 14, 2016, granted, now 10,494,633, issued on Dec. 3, 2019.
Application 15/351,113 is a continuation of application No. PCT/EP2016/077383, filed on Nov. 11, 2016.
Claims priority of application No. 15194367 (EP), filed on Nov. 12, 2015; and application No. 16189502 (EP), filed on Sep. 19, 2016.
Prior Publication US 2023/0296587 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/11 (2006.01); C12N 5/00 (2006.01); C12N 5/074 (2010.01); C12N 5/0793 (2010.01); C12N 5/0797 (2010.01); C12N 15/113 (2010.01); G01N 33/50 (2006.01)
CPC G01N 33/5014 (2013.01) [C12N 5/0018 (2013.01); C12N 5/0619 (2013.01); C12N 5/0623 (2013.01); C12N 5/0696 (2013.01); C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); G01N 33/5058 (2013.01); C12N 2310/11 (2013.01); C12N 2310/20 (2017.05); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/33 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2320/34 (2013.01); C12N 2500/38 (2013.01); C12N 2500/44 (2013.01); C12N 2501/01 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/119 (2013.01); C12N 2501/13 (2013.01); C12N 2501/41 (2013.01); C12N 2501/60 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01); C12N 2503/02 (2013.01); C12N 2506/45 (2013.01); C12N 2533/52 (2013.01)] 26 Claims
OG exemplary drawing
 
1. An antisense oligonucleotide for inducing human paternal ubiquitin-protein ligase E3A (UBE3A) expression, wherein the antisense oligonucleotide comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length with at least 98% complementarity to position 25278410 to 25419462 on human chromosome 15, wherein the oligonucleotide comprises one or more modified nucleosides.